What is the mainstay treatment for KCS?

The mainstay treatment for Keratoconjunctivitis Sicca (KCS), commonly known as dry eye syndrome, involves the use of topical cyclosporine. This medication works by stimulating lacrimal gland function, leading to increased tear production, which is critical in managing KCS. The disease results from a deficiency in tear production, and because tears are essential for maintaining the health of the cornea and conjunctiva, restoring this tear film is crucial for treating the condition.

Topical cyclosporine not only aids in promoting tear production but also has anti-inflammatory properties that help address the inflammatory component often present in KCS. Regular use of this medication can significantly improve the quality of life for animals suffering from this condition.

In contrast, while oral corticosteroids can address inflammation, they do not directly stimulate tear production and can potentially worsen KCS by reducing tear production over time. Systemic antibiotics do not play a role in treating KCS since the condition is not caused by an infection. Cryotherapy is not a recommended treatment for KCS, as it is more suitable for other ophthalmic conditions and does not address the underlying tear deficiency associated with the syndrome.